Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes (REPAMET)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: repaglinide

Study type: Observational

Funder types: Industry

Identifiers

NCT00709917

AGEE-1857

Details and patient eligibility

About

This study is conducted in Europe.

The aim of this observational study is to investigate the switch from metformin alone to metformin combined with repaglinide in type 2 diabetic patients not achieving adequate glycaemic control on maximal dose of metformin given alone and to analyse different epidemiological parameters.

Enrollment: 2,171 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetic patients with inadequate glycaemic control when received metformin alone on maximal dose
• Signed informed consent
• Treatment in accordance with the summary of product characterisation

Exclusion criteria

• Any contraindication to metformin or repaglinide

Trial design

2,171 participants in 1 patient group

A

Treatment:

Drug: repaglinide